Can HCV Viremic Organs Be Used in Liver Transplantation to HCV Negative Recipients?

Muhammad, Haris; Hammami, Muhammad M.; Ting, Peng–Sheng; Şimşek, Cem; Saberi, Behnam; Gürakar, Ahmet

doi:10.21926/obm.hg.2002046

Cited by 4 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4.3 HCV-viremic organs could be considered in: Ø Patients with fulminant hepatitis, or HCC, or patients with low MELD score but had portal hypertension complications (25). Ø Donors exposed to hepatitis C virus (HCV) can be used safely in HCV seronegative liver transplant candidates, provided that treatment is initiated early post LT (26).…”

Section: Utilization Of Hepatitis C -Infected Donor Liversmentioning

confidence: 99%

Future Map of Liver Transplantation

Makhlouf

2023

Global Gastroenterology

View full text Add to dashboard Cite

Liver transplantation (LT) is known to be the final solution for patients suffering from hepatic decompensation and its sequalae. There will be changing trend in liver transplant indications in the future. Non-Alcoholic Steatohepatitis (NASH) related cirrhosis will be the leading indication for LT in Europe, United State and in the Middle East. There will be change in the patient characteristics who are in need for liver transplantation. Liver transplant teams will encounter cases with NAFLD (Non-Alcoholic Fatty Liver Disease) and their linked comorbidity. There will be unmet need for expanding donor pool in the future. Direct-acting antivirals (DAAs) led to dramatic change in HCV treatment and have opened the road for using HCV positive organs as a trial to increase the donor pool. However, to generalize this concept in living donor liver transplant in Countries which had high volume of HCV cases who treated by DAAs as Egypt, this need consensus agreement between different liver transplant centers in the Country. There will be changing trend in NAFLD patient management pre and post liver transplant. There will be expanding role for bariatric surgery specially sleeve gastrectomy before or during LT surgery. Immunosuppression need to be modified and optimized to the patient metabolic risk profile. NAFLD associated comorbidities need specific management preand post-transplant. Multidisciplinary Teamwork will be the key for successful outcome of liver transplant operations.

show abstract

Section: Utilization Of Hepatitis C -Infected Donor Liversmentioning

confidence: 99%

Future Map of Liver Transplantation

Makhlouf

2023

Global Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Long-term survival following LT for viral hepatitis depends on prevention of allograft reinfection[ 53 ]. This is a well-known concept for HBV as well as HCV and can be applied for HDV related LT as well.…”

Section: Liver Transplant Outcomesmentioning

confidence: 99%

Hepatitis D virus and liver transplantation: Indications and outcomes

Muhammad¹,

Tehreem²,

Hammami³

et al. 2021

WJH

Self Cite

View full text Add to dashboard Cite

Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV infection and is associated with significant side effects. Liver transplantation (LT) is the only treatment option for patients with end-stage liver disease, hepatocellular carcinoma, or fulminant hepatitis due to coinfection with HDV. As LT for HDV and hepatitis B virus coinfection is uncommon in the United States, most data on the long-term impact of LT on HDV are from international centers. In this review, we discuss the indications and results of LT with treatment options in HDV patients.

show abstract

“…Another modifiable marginal factor is the donor age. With an, unfortunately, higher incidence of opioid overdose deaths, liver grafts are now coming from younger donors, since opioid use is more common in this age group [ 26 ]. Hence, close post-transplant follows up coupled with the immediate commencement of DAA as soon as HCV is detected is the best strategy that can not only ensure successful utilization of HCV grafts but also deal with a rare, yet severe complication of HCV, namely fibrosing cholestatic hepatitis which can cause rapid graft failure.…”

Section: Donor Grafts Which Are Virally Infectedmentioning

confidence: 99%

An Update on Usage of High-Risk Donors in Liver Transplantation

Muhammad

Zaffar

Tehreem

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

The ideal management for end stage liver disease, acute liver failure, and hepatocellular carcinoma (HCC), within specific criteria, is liver transplantation (LT). Over the years, there has been a steady increase in the candidates listed for LT, without a corresponding increase in the donor pool. Therefore, due to organ shortage, it has been substantially difficult to reduce waitlist mortality among patients awaiting LT. Thus, marginal donors such as elderly donors, steatotic donors, split liver, and donors after cardiac death (DCD), which were once not commonly used, are now considered. Furthermore, it is encouraging to see the passing of Acts, such as the HIV Organ Policy Equity (HOPE) Act, enabling further research and development in utilizing HIV grafts. Subsequently, the newer antivirals have aided in successful post-transplant period, especially for hepatitis C positive grafts. However, currently, there is no standardization, and protocols are center specific in the usage of marginal donors. Therefore, studies with longer follow ups are required to standardize its use.

show abstract

Can HCV Viremic Organs Be Used in Liver Transplantation to HCV Negative Recipients?

Cited by 4 publications

References 30 publications

Future Map of Liver Transplantation

Future Map of Liver Transplantation

Hepatitis D virus and liver transplantation: Indications and outcomes

An Update on Usage of High-Risk Donors in Liver Transplantation

Contact Info

Product

Resources

About